152 related articles for article (PubMed ID: 1477417)
1. Generation of terminal complement complexes in psoriatic lesional skin.
Takematsu H; Tagami H
Dermatology; 1992; 185(4):246-50. PubMed ID: 1477417
[TBL] [Abstract][Full Text] [Related]
2. Impaired expression of erythrocyte glycosyl-phosphatidylinositol-anchored membrane CD59 in patients with psoriatic arthritis. Relation to terminal complement pathway activation.
Triolo G; Accardo-Palumbo A; Sallì L; Ciccia F; Ferrante A; Tedesco L; Sallì S; Giardina E; Pappalardo A; Licata G
Clin Exp Rheumatol; 2003; 21(2):225-8. PubMed ID: 12747280
[TBL] [Abstract][Full Text] [Related]
3. Levels of SC5b--9 complement complex in plasma and synovial fluid of patients with rheumatic disease.
Rus V; Malide D; Boloşiu HD; Parasca I; Duţu AL
Med Interne; 1990; 28(4):305-10. PubMed ID: 2100875
[TBL] [Abstract][Full Text] [Related]
4. Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies.
Koski CL; Sanders ME; Swoveland PT; Lawley TJ; Shin ML; Frank MM; Joiner KA
J Clin Invest; 1987 Nov; 80(5):1492-7. PubMed ID: 3680509
[TBL] [Abstract][Full Text] [Related]
5. Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of human complement.
Hugo F; Krämer S; Bhakdi S
J Immunol Methods; 1987 May; 99(2):243-51. PubMed ID: 3584995
[TBL] [Abstract][Full Text] [Related]
6. Activation of the alternative pathway of complement in psoriatic lesional skin.
Takematsu H; Tagami H
Dermatologica; 1990; 181(4):289-92. PubMed ID: 2073958
[TBL] [Abstract][Full Text] [Related]
7. Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation.
Bovenschen HJ; Seyger MM; Van de Kerkhof PC
Br J Dermatol; 2005 Jul; 153(1):72-8. PubMed ID: 16029329
[TBL] [Abstract][Full Text] [Related]
8. Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium.
Hugo F; Hamdoch T; Mathey D; Schäfer H; Bhakdi S
Clin Exp Immunol; 1990 Jul; 81(1):132-6. PubMed ID: 2379317
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of the membrane and fluid-phase terminal complement complexes C5b-9(m) and SC5b-9. Consequences for interpretation and terminology.
Mollnes TE; Harboe M
Scand J Immunol; 1987 Oct; 26(4):381-6. PubMed ID: 3685888
[TBL] [Abstract][Full Text] [Related]
10. Quantitation of activation of the human terminal complement pathway by ELISA.
Sanders ME; Schmetz MA; Hammer CH; Frank MM; Joiner KA
J Immunol Methods; 1985 Dec; 85(2):245-56. PubMed ID: 2416846
[TBL] [Abstract][Full Text] [Related]
11. Assembly of terminal SC5b-9 complement complexes: a new index of blood-membrane interaction.
Schaefer RM; Rauterberg EW; Deppisch R; Vienken J
Miner Electrolyte Metab; 1990; 16(1):73-6. PubMed ID: 2325595
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive characterization of human stratum corneum of undiseased skin of patients with atopic dermatitis and psoriasis as studied by Fourier transform Raman spectroscopy.
Wohlrab J; Vollmann A; Wartewig S; Marsch WC; Neubert R
Biopolymers; 2001; 62(3):141-6. PubMed ID: 11343282
[TBL] [Abstract][Full Text] [Related]
13. SC5b-7, SC5b-8 and SC5b-9 complexes of complement: ultrastructure and localization of the S-protein (vitronectin) within the macromolecules.
Preissner KP; Podack ER; Müller-Eberhard HJ
Eur J Immunol; 1989 Jan; 19(1):69-75. PubMed ID: 2465906
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of a human endogenous retrovirus E transmembrane envelope glycoprotein in normal, psoriatic and atopic dermatitis human skin.
Bessis D; Molès JP; Basset-Séguin N; Tesniere A; Arpin C; Guilhou JJ
Br J Dermatol; 2004 Oct; 151(4):737-45. PubMed ID: 15491412
[TBL] [Abstract][Full Text] [Related]
15. Elemental analysis mirrors epidermal differentiation.
Forslind B; Werner-Linde Y; Lindberg M; Pallon J
Acta Derm Venereol; 1999 Jan; 79(1):12-7. PubMed ID: 10086851
[TBL] [Abstract][Full Text] [Related]
16. Measurement of Complement Activation via Plasma-Soluble C5b-9 Comparison with Terminal Complement Complex Staining in a Series of Kidney Biopsies.
Wijaya C; Burns C; Hall S; Farmer M; Jones D; Rowlandson M; Choi P; Formby M; de Malmanche T
Kidney Blood Press Res; 2023; 48(1):220-230. PubMed ID: 36917968
[TBL] [Abstract][Full Text] [Related]
17. Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries.
Niculescu F; Hugo F; Rus HG; Vlaicu R; Bhakdi S
Clin Exp Immunol; 1987 Aug; 69(2):477-83. PubMed ID: 3652536
[TBL] [Abstract][Full Text] [Related]
18. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients.
Chiu YY; Nisihara RM; Würzner R; Kirschfink M; de Messias-Reason IJ
J Investig Allergol Clin Immunol; 1998; 8(4):239-44. PubMed ID: 9777539
[TBL] [Abstract][Full Text] [Related]
19. Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin.
Takematsu H; Tagami H
Arch Dermatol; 1993 Jan; 129(1):74-80. PubMed ID: 8420495
[TBL] [Abstract][Full Text] [Related]
20. The terminal complement complex (sC5b-9) is not specifically associated with the development of the adult respiratory distress syndrome.
Parsons PE; Giclas PC
Am Rev Respir Dis; 1990 Jan; 141(1):98-103. PubMed ID: 2297192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
